-
公开(公告)号：US20230295302A1
公开(公告)日：2023-09-21
申请号：US18047216
申请日：2022-10-17
发明人： Prabhu Seshaiyer BHAGAVATHEESWARAN , Nicholas Allan John BOTWOOD , Han CHANG , William J. GEESE , Sabine MAIER , Giovanni SELVAGGI , Joseph Daniel SZUSTAKOWSKI
IPC分类号： C07K16/28 , C12Q1/6886
CPC分类号： C07K16/2818 , C12Q1/6886 , A61K2039/545
摘要： The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.
-
公开(公告)号：US20210101980A1
公开(公告)日：2021-04-08
申请号：US16499540
申请日：2018-03-30
发明人： Prabhu Seshaiyer BHAGAVATHEESWARAN , Nicholas Allan John BOTWOOD , Han CHANG , Yali FU , William J. GEESE , George A. GREEN, IV , Diane HEALEY , Sabine MAIER , Faith E. NATHAN , Abderrahim OUKESSOU , Giovanni SELVAGGI , Joseph Daniel SZUSTAKOWSKI
IPC分类号： C07K16/28 , C12Q1/6886 , A61K39/395 , A61P35/00
摘要： The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-1 antibody or antigen-binding portion thereof. The present disclosure also provides a method for identifying a subject suitable for an immunotherapy, e.g., a treatment with an anti-PD-1 antibody or antigen-binding portion thereof, comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.
-
公开(公告)号：US20220315657A1
公开(公告)日：2022-10-06
申请号：US17699949
申请日：2022-03-21
发明人： Robin EDWARDS , Han CHANG , Michele CLEARY , Peter M. SZABO , Joseph Daniel SZUSTAKOWSKI , Patrik VITAZKA
IPC分类号： C07K16/28 , C07K16/30 , G01N33/574
摘要： This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1 (PD-L1), Serine/Threonine Kinase 11 (STK11), or both PD-L1 and STK11.
-
公开(公告)号：US20220195046A1
公开(公告)日：2022-06-23
申请号：US17599433
申请日：2020-03-27
发明人： Ming LEI , Nathan O. SIEMERS , Dimple PANDYA , Han CHANG , Teresa K. SANCHEZ , Christopher T. HARBISON , Peter M. SZABO , Zachary S. BOYD , Xiaozhong QIAN , Samy Abdel SACI , Tina C. YOUNG , Sujaya SRINIVASAN , Megan M. WIND-ROTOLO , Jasmine RIZZO , Donald G. JACKSON , Alice M. WALSH
摘要： The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or anti-gen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score and a tumor that has a high tumor mutation burden (TMB) status. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.
-
公开(公告)号：US20170306035A1
公开(公告)日：2017-10-26
申请号：US15474731
申请日：2017-03-30
发明人： Zhehong CAI , Indrani CHAKRABORTY , Marie-Michelle Navarro GARCIA , Thomas D. KEMPE , Alan J. KORMAN , Alexander T. KOZHICH , Hadia LEMAR , Mark MAURER , Christina Maria MILBURN , Michael QUIGLEY , Xiang SHAO , Mohan SRINIVASAN , Kent THUDIUM , Susan Chien-Szu WONG , Jochem GOKEMEIJER , Xi-Tao WANG , Han CHANG , Patrick GUIRNALDA
CPC分类号： C07K16/2878 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/574 , G01N2333/70514
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20160347849A1
公开(公告)日：2016-12-01
申请号：US15166114
申请日：2016-05-26
发明人： Zhehong CAI , Indrani CHAKRABORTY , Marie-Michelle Navarro GARCIA , Thomas D. KEMPE , Alan J. KORMAN , Alexander T. KOZHICH , Hadia LEMAR , Mark MAURER , Christina Maria MILBURN , Michael QUIGLEY , Maria RODRIGUEZ , Xiang SHAO , Mohan SRINIVASAN , Brenda L. STEVENS , Kent THUDIUM , Susan Chien-Szu WONG , Jochem GOKEMEIJER , Xi-Tao WANG , Han CHANG , Christine HUANG , Maria JURE-KUNKEL , Zheng YANG , Yan FENG , Patrick GUIRNALDA , Nils LONBERG , Bryan C. BARNHART , Aaron P. YAMNIUK , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL , Praveen AANUR , Mark J. SELBY
CPC分类号： C07K16/2878 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/574
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
摘要翻译： 本文提供了结合OX40的抗体或其抗原结合部分。 还提供了这些蛋白质在治疗应用中的用途，例如在癌症的治疗中。 还提供了产生抗体的细胞，编码抗体的重链和/或轻链可变区的多核苷酸，以及包含编码抗体的重链和/或轻链可变区的多核苷酸的载体。
-
公开(公告)号：US20240301066A1
公开(公告)日：2024-09-12
申请号：US18592208
申请日：2024-02-29
发明人： Prabhu Seshaiyer BHAGAVATHEESWARAN , Nicholas Allan John BOTWOOD , Han CHANG , William J. GEESE , Sabine MAIER , Giovanni SELVAGGI , Joseph Daniel SZUSTAKOWSKI
IPC分类号： C07K16/28 , A61K39/00 , C12Q1/6886
CPC分类号： C07K16/2818 , C12Q1/6886 , A61K2039/545 , C07K2317/76 , C12Q2600/106 , C12Q2600/156
摘要： The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti- PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.
-
公开(公告)号：US20230295737A1
公开(公告)日：2023-09-21
申请号：US18063015
申请日：2022-12-07
发明人： Prabhu Seshaiyer BHAGAVATHEESWARAN , Nicholas Allan John BOTWOOD , Han CHANG , Yali FU , William J. GEESE , George A. GREEN , Diane HEALEY , Sabine MAIER , Faith E. NATHAN , Abderrahim OUKESSOU , Giovanni SELVAGGI , Joseph Daniel SZUSTAKOWSKI
IPC分类号： C12Q1/6886
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-1 antibody or antigen-binding portion thereof. The present disclosure also provides a method for identifying a subject suitable for an immunotherapy, e.g., a treatment with an anti-PD-1 antibody or antigen-binding portion thereof, comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.
-
公开(公告)号：US20230272100A1
公开(公告)日：2023-08-31
申请号：US17819287
申请日：2022-08-11
发明人： Zhehong CAI , Indrani CHAKRABORTY , Marie-Michelle Navarro GARCIA , Thomas D. KEMPE , Alan J. KORMAN , Alexander T. KOZHICH , Hadia LEMAR , Mark MAURER , Christina Maria MILBURN , Michael QUIGLEY , Xiang SHAO , Mohan SRINIVASAN , Kent THUDIUM , Susan Chien-Szu WONG , Jochem GOKEMEIJER , Xi-Tao WANG , Han CHANG , Patrick GUIRNALDA
IPC分类号： C07K16/28 , C07K16/30 , A61P35/00 , A61K39/395 , G01N33/574
CPC分类号： C07K16/2878 , C07K16/30 , C07K16/3069 , C07K16/3038 , C07K16/3023 , A61P35/00 , A61K39/3955 , G01N33/574 , C07K2317/76 , C07K2317/565 , C07K2317/34 , C07K2317/21 , A61K2039/505
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20200325226A1
公开(公告)日：2020-10-15
申请号：US16306380
申请日：2017-06-02
发明人： Robin EDWARDS , Han CHANG , Michele CLEARY , Peter M. SZABO , Joseph D. SZUSTAKOWSKI , Patrik VITAZKA
IPC分类号： C07K16/28 , G01N33/574 , C07K16/30
摘要： This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1 (PD-L1), Serine/Threonine Kinase 11 (STK11), or both PD-L1 and STK11.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.041 秒)
